Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PRF1 | P14222 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | S100A9 | P06702 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 4/20 | 0.42 |
| ▸ | MGAT3 | Q09327 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16996896 | 0.75 | ALPL (0.54) | LMNAPIK3C3THRBPIK3CAACLY | |
| SCHEMBL740363 | 0.75 | MEN1 (0.61) | LMNAPIK3C3THRBPIK3CAACLY | |
| SCHEMBL454986 | 0.74 | LMNA (0.49) | LMNAPIK3C3THRBPIK3CAPRF1 | |
| SCHEMBL18131006 | 0.74 | LMNA (1.00) | LMNAPIK3C3THRBPIK3CAACLY | |
| SCHEMBL29463837 | 0.74 | LMNA (1.00) | LMNAPIK3C3THRBPIK3CAACLY | |
| SCHEMBL5801171 | 0.74 | LMNA (0.61) | LMNATHRBTSHRKMT2AMGAT2 | |
| SCHEMBL25407126 | 0.74 | LMNA (0.42) | LMNAPIK3C3THRBPIK3CAS100A9 | |
| SCHEMBL30504905 | 0.74 | LMNA (0.42) | LMNAPIK3C3THRBPIK3CAS100A9 | |
| SCHEMBL12459512 | 0.73 | LMNA (0.60) | LMNATHRBACLYMOGAT2KMT2A | |
| SCHEMBL23833459 | 0.73 | SLC22A12 (0.58) | S100A9KDM1AMAOATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| EP-2888251-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014028968-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-02-27 | — | — | WO | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | LMNA 3236/4885PIK3C3 19/4885THRB 4684/4885 |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, BAK1 | LMNA 264/4885PIK3C3 1348/4885THRB 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.